In Silico Identification of Inhibitors as Antagonist for HCV Treatment

HCV virus is a major cause of liver damage which leads to the Hepatocellular Carcinoma and in most of the cases death of patient. NS3 protein widely recognised for its important role in replication of the virus. The current study deals with the pharmacological analysis and preclinical trials of inhibitors by using in silico techniques. The objective of this study is to screen the potential inhibitors and design a drug against NS3 protein of HCV. The 3D structure was predicted by using SWISS MODEL and further validated using Ramachandran score. COACH server was used to find out active site informations. Further docking studies were done to validate the potency of inhibitors. The results indicate that the designed ligand is a potential HCV anatagonist. The study could lead to the further development of potent HCV antagonist for the treatment of Hepatitis.